Items Tagged ‘Kisqali® Femara®’

May 31st, 2017

FDA Approves First-of-its-kind Kisqali® Femara® Co-Pack For Initial Treatment Of HR+/HER2- Advanced or Metastatic Breast Cancer

By

The US Food and Drug Administration (FDA) has approved the Kisqali ®Femara ® Co-Pack (ribociclib tablets; letrozole tablets) for the treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women 1. The Kisqali-Femara Co-Pack is the first, and only currently available, combination pack with two prescription products in advanced breast […]

View full entry

Tags: Advanced Metastatic Breast Cancer, Breast Cancer, HER2 neu negative, HR+, Kisqali® Femara®, News